# To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia

> **NCT05890053** · PHASE3 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 301 (actual)

## Conditions studied

- Peripheral Neuropathic Pain

## Interventions

- **DRUG:** HSK16149 40mg BID

## Key facts

- **NCT ID:** NCT05890053
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-17
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-08-07
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05890053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05890053, "To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05890053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*